Welcome to our dedicated page for Unicycive Therapeutics SEC filings (Ticker: UNCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a 200-page biotech filing packed with clinical trial minutiae and cash-runway calculations is tough鈥攅specially when Unicycive Therapeutics鈥� renal drug pipeline means every 10-K hides critical FDA milestones. If you have ever wondered, 鈥淗ow do I follow Unicycive Therapeutics insider trading Form 4 transactions or locate their latest quarterly earnings report 10-Q filing?鈥�, you are not alone.
Stock Titan solves that problem. Our platform delivers AI-powered summaries that explain complex disclosures in plain language, flagging trial outcomes, patent extensions, and liquidity updates the moment Unicycive Therapeutics posts an 8-K. Need the big picture? The annual report 10-K simplified section highlights R&D spend and risk factors. Looking for specifics? Form 4 insider transactions appear in real-time, so you can track executive stock moves before the market reacts. Key long-tail resources include:
- Unicycive Therapeutics SEC filings explained simply鈥攅very form, every footnote
- Unicycive Therapeutics earnings report filing analysis that links quarter-over-quarter trial costs to cash burn
- Under颅standing Unicycive Therapeutics SEC documents with AI鈥攏o jargon required
Investors use these insights to monitor drug-development timelines, compare segment expenses, and gauge dilution risk from future capital raises. Whether you need Unicycive Therapeutics executive stock transactions Form 4, a proxy statement executive compensation breakdown, or Unicycive Therapeutics 8-K material events explained, our real-time feed and expert commentary keep you ahead. Save hours, stay informed, and make better decisions about this kidney-focused biotech鈥攁ll in one place.
Unicycive Therapeutics reported that it has issued a press release announcing its financial results for the three months ended June 30, 2025 and provided a business update. The company furnished that press release as Exhibit 99.1 to its Form 8-K and clarified the disclosure is being furnished, not filed for purposes of the Exchange Act and will not be incorporated by reference into registration statements, except as expressly stated. The Form 8-K also identifies the company as an emerging growth company.
Unicycive Therapeutics (UNCY) reported interim financial results for the quarter ended June 30, 2025 showing $22.3 million in cash and total assets of $30.0 million, down slightly from $31.7 million at year-end. Total liabilities fell materially to $13.6 million from $24.2 million, driven largely by a decline in the warrant liability from $18.9 million to $10.2 million, which reduced reported expense volatility.
The company recorded a six-month net loss of $5.9 million, an improvement from a $11.1 million loss in the prior-year period, as operating expenses decreased to $15.0 million from $16.6 million. Cash used in operating activities was $17.3 million for the six months, and net cash provided by financing activities was $13.5 million, including $12.6 million from a secondary offering. Management states it believes it has sufficient resources for at least one year under current plans. The filing also discloses a 1-for-10 reverse stock split effective June 20, 2025 and ongoing reliance on future financing to complete development and commercial efforts.
Octagon Capital Advisors LP and related funds and principal Ting Jia report beneficial ownership of 1,000,000 shares of Unicycive Therapeutics, Inc. (UNCY), representing 7.8% of the outstanding common stock based on 12,768,239 shares outstanding as reported by the issuer. Octagon is the investment manager of the funds and Mr. Jia is the managing member of Octagon, and by virtue of those relationships Octagon and Mr. Jia may be deemed to beneficially own the shares held by the funds.
The filing discloses that the reported holdings are held with shared voting and dispositive power rather than sole power. The ownership is allocated as 650,000 shares (5.1%) held by Octagon Investments Master Fund LP and 350,000 shares (2.7%) held by Octagon Private Opportunities Fund II LP. The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
FAQ
What is the current stock price of Unicycive Therapeutics (UNCY)?
What is the market cap of Unicycive Therapeutics (UNCY)?
